Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer.
J Thorac Oncol
; 9(1): 126-31, 2014 Jan.
Article
em En
| MEDLINE
| ID: mdl-24346102
ABSTRACT
INTRODUCTION:
In this phase II study, patients with stage IIIB/IV non-small-cell lung cancer were randomly assigned (111) to receive LY293111 (200 mg twice daily [200 LY293111] or 600 mg twice daily [600 LY293111]) or placebo for 7 days, followed by concurrent cisplatin (75 mg/m2; day 1) and gemcitabine (1250 mg/m2; days 1 and 8), every 21 days.The primary endpoint was progression-free survival, (PFS), with 75% power to detect 33% improvement compared with placebo (5 months).METHODS:
Of 200 randomized patients, 195 were treated. Demographics were well balanced across treatment arms 65% of the patients were men; median age was 62 years; 85% had stage IV disease; and patients had an Eastern Cooperative Oncology Group performance status of 0 (36%) or 1 (64%).RESULTS:
The most frequent study drug-related toxicities were nausea, vomiting, and fatigue. Response rates were similar across treatment arms (200 LY293111 20%; 600 LY293111 25%; placebo 31%).CONCLUSIONS:
Median PFS (95% confidence interval) was not significantly different across treatment arms (200 LY293111 4.6 months [3.2-5.0]; 600 LY293111 5.6 months [4.1-6.8]; placebo 6.0 months [5.2-7.5]). LY293111 combined with gemcitabine-cisplatin did not increase median PFS compared with placebo plus gemcitabine-cisplatin in patients with non-small-cell lung cancer.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Protocolos de Quimioterapia Combinada Antineoplásica
/
Carcinoma Pulmonar de Células não Pequenas
/
Neoplasias Pulmonares
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Thorac Oncol
Ano de publicação:
2014
Tipo de documento:
Article
País de afiliação:
Alemanha